Please upgrade your browser.
Researchers have developed a promising titanium and gold based compound that destroys kidney cancer cells, while leaving normal cells unharmed.
The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer.
Investment—not good intentions—fuels high-risk research, and price controls will limit new therapies.
Following progression on first-line therapy, patients with renal cell carcinoma (RCC) often do not need to be hurried to second-line treatment, says David F. McDermott, MD. If there is existing disease that is not harming the patient, and the patient feels well, there is no reason to switch therapies, adds Eric Jonasch, MD.
Today's Penn State football news features a look at defensive coordinator Bob Shoop, who announced via Twitter Friday that every sack registered by the Nittany Lions defense will result in a $107 donation to help fight kidney cancer
The Young Investigator Award (YIA) is a one-year research grant totaling $50,000, paid in two equal installments to the awardee’s institution.
"The link between tobacco and cancer is widely known and readily accepted by the public but many are not yet fully convinced that healthy eating, regular exercise and not drinking alcohol can lower your cancer risk."
Developmental factors in the womb, and during childhood and adolescence, that influence growth are linked to an increased risk...
Up to now, the role of miR‐372 in renal cell carcinoma has remained unknown; in this study, we have aimed to reveal its functional importance in this tumour.
NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients
|NeonCRM by Neon One|